Topics

Crossover Study of Propranolol vs Ivabradine in POTS

2019-12-10 01:20:58 | BioPortfolio

Summary

1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typically resolve when sitting or lying down. Most importantly, POTS is associated with a very poor quality of life and significant functional disability. POTS patients commonly experience mental clouding ("brain fog") even while lying down or seated, which poses significant limitations to daily activities .

Unfortunately, there is a relative paucity in the literature assessing therapies for POTS patients. Given that excessive tachycardia on standing is a fundamental component of this syndrome, a handful of studies have evaluated medications that reduce HR. Ivabradine is newer drug that is a selective If channel blocker that reduces HR without affecting other cardiovascular functions.

2.0 RATIONALE / STUDY PURPOSE The investigators propose to compare the efficacy of propranolol and ivabradine on HR response to standing, and symptom burden in patients with POTS.

3.0 Study Design This will be a single-center double-blind placebo-controlled randomized crossover trial conducted in patients with POTS to compare effects of (1) oral ivabradine 5 mg bid plus placebo BID (to fill out a QID schedule); (2) oral propranolol 20 mg qid; and (3) oral placebo qid in POTS patients. After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of either ivabradine, propranolol or placebo. The other two treatments will be given in separate 4-week courses with a 7-day washout period between phases, with each participant acting as his or her own control. At the end of each 4-week phase, participants will complete the symptom-rating and HRQOL questionnaires, and also undergo tilt table testing to assess the change in HR at 10 min with head up tilt.

Participants will undergo POTS testing at baseline and at the end of each 4-week treatment course. This will involve a total of 4 separate study visits.

Description

1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typically resolve when sitting or lying down. Most importantly, POTS is associated with a very poor quality of life and significant functional disability. POTS patients commonly experience mental clouding ("brain fog") even while lying down or seated, which poses significant limitations to daily activities .

Unfortunately, there is a relative paucity in the literature assessing therapies for POTS patients. Given that excessive tachycardia on standing is a fundamental component of this syndrome, a handful of studies have evaluated medications that reduce HR. In a randomized crossover study of 54 patients with POTS, low-dose propranolol (10-20 mg PO) was found to acutely reduce standing HR compared to placebo. Further, there was greater improvement in symptom burden (quantified using the Vanderbilt Orthostatic Symptom Score [VOSS]) from baseline to 2 hours in patients treated with propranolol compared to placebo.

Ivabradine is newer drug that is a selective If channel blocker that reduces HR without affecting other cardiovascular functions. In non-randomized reports, it has been shown to improve symptoms in patients with POTS. In a case series of 22 patients, approximately 60% of patients with POTS treated with ivabradine had symptom improvement

2.0 RATIONALE / STUDY PURPOSE Patients with POTS suffer great disability and currently used pharmacologic therapies require more rigorous study. Currently, there are no studies comparing the relative efficacy of propranolol and ivabradine in patients with POTS.

We propose to compare the efficacy of propranolol and ivabradine on HR response to standing, and symptom burden in patients with POTS. This would be the first study to compare the relative efficacy of ivabradine to propranolol in POTS. The results of this exploratory study may help inform design of a larger multicenter clinical trial investigating the use of ivabradine or propranolol in POTS over time. We will test the null hypothesis that the heart rate lowering response to ivabradine is not different than the heart lowering response of propranolol.

In addition, we propose to assess sleep complaints and sleep quality using questionnaire and actigraphy based assessments.

3.0 Study Design This will be a single-center double-blind placebo-controlled randomized crossover trial conducted in patients with POTS to compare effects of (1) oral ivabradine 5 mg bid plus placebo BID (to fill out a QID schedule); (2) oral propranolol 20 mg qid; and (3) oral placebo qid in POTS patients. After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of either ivabradine, propranolol or placebo. The other two treatments will be given in separate 4-week courses with a 7-day washout period between phases, with each participant acting as his or her own control. At the end of each 4-week phase, participants will complete the symptom-rating and HRQOL questionnaires, and also undergo tilt table testing to assess the change in HR at 10 min with head up tilt.

Participants will undergo POTS testing at baseline and at the end of each 4-week treatment course in the Libin Cardiovascular Institute TRW Human Physiology Research space. This will involve a total of 4 separate study visits.

- Studies will start between 8-9am, with the patient in a fasting state (to avoid acute hemodynamic effects from eating).

- Prior to hemodynamic data collection, a brief medical history will be conducted to ensure that the medications have not changed, and that there are not new medical issues that would make the study unsafe or imprudent.

- Participants will be instrumented for continuous beat-to-beat BP and electrocardiographic monitoring. BP will be monitored continuously using a finger volume clamp method (Nexfin, BMEYE Inc.) and calibrated with intermittent brachial cuff measurements using a standard automatic BP monitor (IVY Model 450C, IVY Medical, Branford, CT, USA).

- Baseline seated continuous data (EKG signals and continuous BP will be collected for ~10 min).

- Oxygen saturation will be assessed from a finger probe. End-tidal CO2 will be measured using nasal prongs.

- If enrolled in the NVC sub-study:

- In addition to hemodynamic data collection, we will collect posterior cerebral artery (PCA) blood flow velocity using Transcranial Doppler (TCD) monitoring.

- Baseline hemodynamic measures, and baseline neurovascular coupling (NVC) testing (see section 5.5.2 below) via posterior cerebral artery blood flow monitoring and baseline Stroop incongruence testing (see section 5.5.3) will be performed with the patient is supine.

- The patient will then be strapped onto the tilt table and then tilted to 80° head-up for 10 minutes with continuous hemodynamic data collection. VOSS ratings will be collected at the end of tilt.

- If enrolled in the NVC sub-study,

o Neurovascular coupling testing and Stroop Incongruence scores will be collected at the end of the tilt.

- Neuropsychological testing of the cognitive domains of memory, attention and executive function will be assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB).

- Participants will be asked to comment on any side effects or unrated symptoms.

- Participants and the research staff will be asked to "guess" at which intervention was given on that study day (not applicable to baseline visit).

- After the study is finished, we will remove the recording patches, and electrodes. This testing day will last about 1-2 hours.

Upon conclusion of the tilt testing, we will connect patients to a 24-hour Holter monitor for continuous ECG and HR monitoring. Participants will return the monitoring device the following day.

This testing protocol will be repeated at baseline, and at the end of phase 1, 2, and 3 with different study drugs.

Study Design

Conditions

Postural Tachycardia Syndrome

Intervention

Ivabradine 4-week course, Propranolol 4-week course, Placebo 4-week course

Status

Not yet recruiting

Source

University of Calgary

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-12-10T01:20:58-0500

Clinical Trials [7457 Associated Clinical Trials listed on BioPortfolio]

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, We...

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected...

Tolcapone in Obsessive Compulsive Disorder

The proposed study will consist of a 5-week double-blind cross-over study trial of tolcapone in 20 people (ages 18-65). The study will be divided into an initial 2 week phase and a second ...

Dose Response Study in Japanese Patients

This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients w...

Milk Thistle in Body Dysmorphic Disorder

The proposed study will consist of a 9 week double-blind cross-over study trial of milk thistle in 15 people (ages 18-65). The study will be divided into an initial 4 week phase, a one wee...

PubMed Articles [2657 Associated PubMed Articles listed on BioPortfolio]

Early score fluctuation and placebo response in a study of major depressive disorder.

Early score fluctuation in double-blind, placebo-controlled studies may affect the reliability of the baseline measurement and adversely affect the eventual study outcome. We examined the effect of ea...

The influence of chronic intermittent hypoxia on hypothalamic-somatotropic axis in rats.

To investigate the effects of chronic intermittent hypoxia on somatotropic axis hormone levels in rats. Mature male Wistar rats were exposed to air or intermittent hypoxia randomly.The serum levels o...

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.

Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks.

Association of Widespread Adoption of the 39-Week Rule With Overall Mortality Due to Stillbirth and Infant Death.

To improve neonatal morbidity, efforts have been made to reduce elective deliveries prior to 39 weeks' gestation, also known as the 39-week rule. Prolonging pregnancies also prolongs exposure to the r...

Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study.

Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatit...

Medical and Biotech [MESH] Definitions

Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.

Deaths occurring from the 28th week of GESTATION to the 7th day after birth.

A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.

Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.

The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation.

More From BioPortfolio on "Crossover Study of Propranolol vs Ivabradine in POTS"

Quick Search

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial